Flora Growth Corp. (NASDAQ:FLGC – Free Report) – Analysts at Roth Capital decreased their Q2 2025 earnings estimates for Flora Growth in a report issued on Wednesday, August 14th. Roth Capital analyst W. Kirk now forecasts that the company will post earnings per share of $0.07 for the quarter, down from their prior estimate of $0.14. The consensus estimate for Flora Growth’s current full-year earnings is ($0.30) per share. Roth Capital also issued estimates for Flora Growth’s Q3 2025 earnings at $0.08 EPS, Q4 2025 earnings at $0.08 EPS and FY2025 earnings at $0.34 EPS.
Several other equities analysts also recently weighed in on the stock. Roth Mkm reiterated a “buy” rating and issued a $6.00 target price (down previously from $7.00) on shares of Flora Growth in a research note on Thursday, May 16th. Alliance Global Partners restated a “neutral” rating on shares of Flora Growth in a research report on Thursday.
Flora Growth Stock Performance
FLGC opened at $0.92 on Thursday. The company has a current ratio of 1.13, a quick ratio of 0.65 and a debt-to-equity ratio of 0.58. The firm has a 50-day moving average price of $1.02 and a 200-day moving average price of $1.26. Flora Growth has a twelve month low of $0.63 and a twelve month high of $5.48.
Flora Growth (NASDAQ:FLGC – Get Free Report) last posted its earnings results on Tuesday, May 14th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The business had revenue of $18.03 million during the quarter, compared to analysts’ expectations of $19.04 million. Flora Growth had a negative return on equity of 144.44% and a negative net margin of 75.95%.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Flora Growth stock. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Flora Growth Corp. (NASDAQ:FLGC – Free Report) by 66.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 988,368 shares of the company’s stock after buying an additional 393,780 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned approximately 12.04% of Flora Growth worth $1,334,000 as of its most recent SEC filing. Institutional investors own 36.01% of the company’s stock.
About Flora Growth
Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.
Further Reading
- Five stocks we like better than Flora Growth
- Why is the Ex-Dividend Date Significant to Investors?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- What is a Low P/E Ratio and What Does it Tell Investors?
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- Pros And Cons Of Monthly Dividend Stocks
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Flora Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flora Growth and related companies with MarketBeat.com's FREE daily email newsletter.